Effect of Desloratadine Citrate Disodium in the treatment of chronic urticaria
ZHANG Chao1 ZHANG Lin-lin2 DAI Wei-wei3 LIU Hong3▲
1. Department of Pharmacy, Jiujiang First People′s Hospital, Jiangxi Province, Jiujiang 332000, China;
2. Department of Out-patient, Jiujiang Economic Zone Ruili Medical Cosmetology Center, Jiangxi Province, Jiujiang 332000, China;
3. Department of Dermatology, Jiujiang First People′s Hospital, Jiangxi Province, Jiujiang 332000, China
AbstractObjective To explore the effect of Desloratadine Citrate Disodium on chronic urticaria. Methods A total of 100 patients with chronic urticaria who were admitted to the Department of Dermatology of Jiujiang First People′s Hospital from January 2019 to January 2021 were selected as subjects and divided into the control group and the study group by the random number table method, with 50 patients in each group. The control group was treated with Loratadine Tablets, and the study group was treated with oral Desloratadine Citrate Disodium Tablets. Both groups were treated continuously for 28 days. The total score, pruritus score, wheal number, wheal size, total effective rate of different treatment courses and the levels of transforming growth factor-β1 (TGF-β1), immunoglobulin E (IgE), T cell subsets and interleukin-18 (IL-18) were compared between the two groups before treatment, 14 and 28 days after treatment. Results The pruritus scores, wheal number scores, wheal size scores and total scores of the two groups at 14 and 28 d after treatment were lower than those before treatment, with statistically significant differences (P<0.05). The pruritus score, wheal number score, wheal score and total score of the study group were all lower than those of the control group at 14 and 28 d after treatment, with statistically significant differences (P<0.05). In the two groups, the total effective rates at 28 d after treatment were higher than those at 14 d after treatment, with statistically significant differences (P<0.05). The total effective rates in the study group were higher than those in the control group at 14 and 28 d after treatment, with statistically significant differences (P<0.05). The TGF-β1, IgE, IL-18 and CD8+ in the two groups at 14 and 28 d after treatment were lower than those before treatment, with statistically significant differences (P<0.05). The TGF-β1, IgE IL-18 and CD8+in the study group were lower than those in the control group at 14 and 28 d after treatment, with statistically significant differences (P<0.05).The levels of CD4+ and CD4+/CD8+ in the two groups at 14 and 28 d after treatment were higher than those before treatment, with statistically significant differences (P<0.05).The levels of CD4+ and CD4+/CD8+ in the study group were higher than those in the control group at 14 and 28 d after treatment, with statistically significant differences (P<0.05). Conclusion Desloratadine Citrate Disodium can effectively regulate the levels of serum TGF-β1, IgE, IL-18 and T cell subsets of CD4+, CD8+, and CD4+/CD8+ in patients with chronic urticaria, showing good clinical efficacy.
ZHANG Chao,ZHANG Lin-lin,DAI Wei-wei, et al. Effect of Desloratadine Citrate Disodium in the treatment of chronic urticaria[J]. 中国当代医药, 2021, 28(34): 162-166.
EL-Mezayen RE，Matsumoto T.In vitro responsiveness to IL-18 in combination with IL-12 or IL-2 by PBMC from patients with bronchial asthma and atopic dermatitis[J].Clin Immunol，2004，111（1）：61-68.
